Search company, investor...
Gerson Lehrman Group company logo

Gerson Lehrman Group

glginsights.com

Founded Year

1998

Stage

Private Equity - II | Alive

Total Raised

$692M

Valuation

$0000 

Last Raised

$212M | 7 yrs ago

Revenue

$0000 

About Gerson Lehrman Group

Gerson Lehrman Group (GLG), founded in 1998, is a technology-enabled learning platform that connects professionals with experts. Companies use GLG to help solve strategic and operational challenges, test hypotheses, gain market feedback, and seek mentorship.

Headquarters Location

60 East 42nd Street 3rd Floor

New York, New York, 10022,

United States

212-984-8500

Missing: Gerson Lehrman Group's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Gerson Lehrman Group's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing Gerson Lehrman Group

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Gerson Lehrman Group in 3 CB Insights research briefs, most recently on Dec 1, 2021.

Gerson Lehrman Group Patents

Gerson Lehrman Group has filed 3 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/24/2012

12/31/2013

Grant

Application Date

7/24/2012

Grant Date

12/31/2013

Title

Related Topics

Status

Grant

Latest Gerson Lehrman Group News

Fourth COVID-19 vaccination protects patients with cancer

Oct 17, 2022

Disclosures: Austrian Federal Ministry for Digital and Economic Affairs; Christian Doppler Research Association; Medical University of Vienna; National Foundation for Research, Technology and Development; and Südtiroler Sanitätsbetriebt supported the study. Preusser reports personal fees from AbbVie, Adastra, AstraZeneca, Bayer, BMJ Journals, Bristol Myers Squibb, CMC Contrast, Daiichi Sankyo, Eli Lilly, Gan & Lee Pharmaceuticals, Gerson Lehrman Group, GSK, Medahead, MedMedia, Merck Sharp & Dohme, Mundipharma, Novartis, Roche, Sanofi and Tocagen outside the submitted work. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio A fourth dose of the COVID-19 vaccine increased humoral immunity among patients with solid and hematologic cancers, according to study results published in JAMA Oncology. However, passive immunization with the long-acting monoclonal antibodies tixagevimab and cilgavimab (Evusheld; AstraZeneca) did not appear effective against omicron sublineages BA.1 and BA.4, researchers noted. “We recommend a fourth COVID-19 vaccine dose to our patients with solid and hematologic cancers, based on our findings,” researcher Matthias Preusser, MD, told Healio. Source: Adobe Stock Background and methods “We and other groups showed earlier this year that a third vaccination dose increased humoral immunity against COVID-19 in patients with cancer ,” Matthias Preusser, MD, professor of medical oncology and head of the clinical division of oncology at Medical University of Vienna, told Healio. “However, new virus variants of concern keep emerging and are a particular threat to immunocompromised patients, such as those with cancer. We therefore sought to investigate whether a fourth vaccine dose, or antibody-based preexposure prophylaxis, was capable of increasing the immunity in this patient population.” Matthias Preusser Preusser and colleagues compared antibody levels against the receptor-binding domain of the spike protein of COVID-19 hu-1 and omicron sublineages BA.1 or BA.4 among 72 patients (median age, 74 years; 65.3% men) with cancer who received a fourth dose of COVID-19 vaccination (n = 54) or tixagevimab and cilgavimab (n = 18). Most of those who received the fourth vaccination (n = 33) had hematologic malignant neoplasms, whereas 21 had solid tumors. Investigators also assessed the inhibition of the interaction between receptor-binding domains and the receptor angiotensin-converting enzyme 2. Findings Results showed median anti-receptor-binding domains increased from before to after fourth vaccination against omicron sublineages BA.1 (0.154 optical density to 0.969 optical density; P = .02) and BA.4 (0.245 to 0.966; P = .02) among patients with hematologic malignant neoplasms undergoing B cell–targeted therapy. Of note, researchers observed no other differences in antibody levels among those with other hematologic diseases. Among those with solid malignant neoplasms, researchers identified pronounced increases in median anti-receptor-binding domains before vs. after the fourth vaccination dose against variants hu-1 (1.157 optical density vs. 1.438 optical density; P = .02), BA.1 (0.721 vs. 1.026; P = .003) and BA.4 (0.556 vs. 1.22; P = .002). Moreover, the potential inhibition of the interaction between receptor-binding domains and the receptor angiotensin-converting enzyme 2 appeared higher after the fourth vaccination dose among patients with hematologic disease and solid tumor cancers, especially for sublineages BA.1 and BA.4, according to the researchers. Researchers further observed median inhibition of receptor-binding domains and the receptor angiotensin-converting enzyme 2 with tixagevimab and cilgavimab of 99.9% for sublineage hu-1, 34.9% for BA.1 and 15.4% for BA.4. “We recommend a fourth COVID-19 vaccine dose to our patients with solid and hematologic cancers, based on our findings,” Preusser said. “However, we discourage passive immunization with tixagevimab and cilgavimab, because we saw very limited blocking activity against currently circulating COVID-19 variants.” Future research Next steps include the examination of the cellular immune response to the fourth vaccination dose to obtain a better understanding of the potential memory effects on the immune system, Preusser said. “In addition, we are planning studies on long-COVID-19 and humoral immune responses to adapted vaccines and a fifth vaccination dose, which is also already being considered in immunocompromised individuals,” he added. For more information

Gerson Lehrman Group Frequently Asked Questions (FAQ)

  • When was Gerson Lehrman Group founded?

    Gerson Lehrman Group was founded in 1998.

  • Where is Gerson Lehrman Group's headquarters?

    Gerson Lehrman Group's headquarters is located at 60 East 42nd Street, New York.

  • What is Gerson Lehrman Group's latest funding round?

    Gerson Lehrman Group's latest funding round is Private Equity - II.

  • How much did Gerson Lehrman Group raise?

    Gerson Lehrman Group raised a total of $692M.

  • Who are the investors of Gerson Lehrman Group?

    Investors of Gerson Lehrman Group include SFW Capital Partners, Silicon Valley Bank, Silver Lake, Bessemer Venture Partners and Princeton Ventures.

  • Who are Gerson Lehrman Group's competitors?

    Competitors of Gerson Lehrman Group include Enquire AI, Tegus, techspert.io, Arbolus, MDisrupt, Sealed Network, Inex One, Lynk, Atheneum, Coleman Research Group and 13 more.

Compare Gerson Lehrman Group to Competitors

Tegus Logo
Tegus

Tegus is an online professional learning platform that provides institutional investors access to industry experts across the globe including workflows to surface and analyze data from SEC filings, as well as expert interview services. It offers users to explore new actionable investment ideas, view questions from peers, and engage with experts. It caters to a wide range of customers worldwide, including investment firms, corporations, and consultancies. The company was founded in 2017 and is based in Chicago, Illinois.

AlphaSights Logo
AlphaSights

AlphaSights has established itself as the go-to knowledge partner for some of the largest consultancies, private equity funds, investment banks and corporations in the world, helping them access the knowledge they need to make better, more informed, investment decisions.

Third Bridge Logo
Third Bridge

Third Bridge provides private equity firms, hedge funds, and strategy consultants with access to experts via their expert network. The company's Forum product offers a subscription to call transcripts conducted by their team with experts in various spaces.

proSapient Logo
proSapient

proSapient is a machine learning research platform that helps partners conduct primary research around the globe.

S
Sealed Network

Sealed is an expert network fully focused on Southeast Asia. They connect localized subject-matter industrial professionals to businesses requiring insights into the region.

Lynk Logo
Lynk

Lynk is a business advice platform dedicated to connecting people to the right experts for advice, insights, and knowledge The company's AI-driven knowledge management platform enables efficient access to expertise and knowledge at scale, creating a platform to seek, build and share credible human expertise. Its product offerings, Answers and Circle, give enterprises fast, convenient, and cost-effective ways to organize, connect and engage with individuals that have relevant expertise and experience. Lynk was founded in 2015 and is based in New York, New York.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.